Australian biotech market watch 07/10/09
Wednesday, 07 October, 2009
Swings and roundabouts. The All Ordinaries has seen a strong bounce today, recovering from its sharp drop Friday last week. As of 4.15pm it's up over 2% to 4,696.
Much of the gain is attributed to the Reserve Bank's surprise lift in the cash rate by 25 basis points, which is a strong indication that colour is returning to the cheeks of the Australian economy.
However, the good news didn't reach the health sector, with the benchmark S&P/ASX 200 Health Care staying relatively level for the day, down 2.4% for the week.
Ramsay Health Care (ASX:RHC) led the way with a 1.5% drop, down 16c to $10.57. Cochlear (ASX:COH) was close behind, shedding 1.1% to $65.69. CSL (ASX:CSL) was steady at $32.64.
Vision therapeutics specialists, pSivida (ASX:PVA) lost another 3.4% to $3.67 today, down 37% from its peak of $6.29 on September 22.
It wasn't all bad news, though. Ansell (ASX:ANN) continued its run of gains over the last month, rising 12c to $10.06. Blackmores (ASX:BKL) is also up 10c from its close yesterday to $20.42.
Anti-influenza pharma company, Biota Holdings (ASX:BTA), has had a spectacular year, up an astounding 769% since January 1, and up another 2.8% to $2.91 today in a day of moderately heavy trading.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
